Clinically, CRP serves as a biomarker for systemic inflammation, with plasma levels rising from <5 mg/L in healthy individuals to >200 mg/L in severe sepsis or trauma. Elevated baseline high-sensitivity CRP (hs-CRP >3 mg/L) predicts cardiovascular events, correlating with atherosclerosis progression and endothelial dysfunction. In oncology, CRP >10 mg/dL portends poor prognosis in pancreatic cancer, reflecting tumor-associated inflammation. CRP also links metabolic dysregulation, with levels >2.9 mg/L increasing type 2 diabetes risk via IL-6-mediated insulin resistance 6. Autoimmune disorders like rheumatoid arthritis show CRP elevation proportional to disease activity, while Alzheimer’s disease involves CRP binding amyloid-β plaques to modulate neuroinflammation.

Common uses include IVD standards, calibrators, and controls.